生殖生物学は、ハードテック分野における重要なフロンティアとして台頭しており、生殖医療の提供方法を根本から変える可能性を秘めています。Dioseve社はまさにその2領域で事業を促進しており、Pangaea Venturesは同社への新たな投資を通じてその取り組みを支援させて頂きます。これは、Pangaeaにとって日本初のスタートアップ投資であり、日本においてより多くのハードテック創業者を支援するための基盤を整えてきた成果でもあります。

Reproductive biology is emerging as an important frontier in hard tech, with the potential to reshape how fertility care is delivered. Dioseve is building at that intersection, and Pangaea Ventures is pleased to support that work through a new investment in the company, our first startup investment in Japan where we have been laying the groundwork to support more hard tech founders in the country.

Pangaea Venturesが日本初のスタートアップ投資を完了。治療負担の軽減と患者・医療機関双方の改善を目指す体外成熟アプローチ、Dioseve社の生殖医療プラットフォームの発展を支援。

Pangaea Ventures today announced it joined Dioseve’s $7 million (JPY 1.0 billion) Series A Extension financing round, alongside participation from Archetype Ventures, DG Daiwa Ventures, Mirai Door (Asuka Innovation Fund), D4V, and Shionogi & Co., Ltd. Dioseve is a biotechnology company developing a new approach to fertility treatment grounded in stem cell biology and reproductive medicine.

Pangaea Venturesは白博堂およびCorundum Systems Biologyとともに、2026年6月24日（火）午後4時（PT）（日本標準時：6月25日午前8時）にオンラインウェビナーを開催します。PangaeaパートナーのAndrew Haughianが登壇し、AI、半導体、および周辺インフラにおけるグローバルなハードテック機会をどのようにマッピングしているか、またその変革から成る「新規事業の機会を見守る」立場から「新規事業を形成する」立場へと移行したい日本のコーポレートベンチャー・戦略リーダーにとって何を意味するかを共有します。

Pangaea Ventures is joining Hakuhodo and Corundum Systems Biology for an online webinar on June 24 at 4pm PT (8am June 25 Japan Standard Time), featuring Pangaea Partner Andrew Haughian. Andrew will share how our team has mapped global hard tech opportunities in AI, semiconductors, and adjacent infrastructure.

After 26 years building Pangaea Ventures, Chris Erickson will step back from full-time engagement at the end of June. He will remain involved in portfolio management, continue to oversee and manage the portfolio companies he is currently working with, and stay on the investment committees for Pangaea's funds. 

Nautilus validated its next‑generation EcoCore cooling unit for Vera Rubin‑class AI GPU clusters, proving it can safely and efficiently handle 4 MW‑plus high‑density workloads that legacy systems struggle to support.

Pangaea co-hosted the inaugural Canadian Climate Capital Summit, bringing together over 200 LPs, investors, capital allocators, founders, and ecosystem builders in one of the largest gatherings of hard tech and climate tech capital in Canada. Here are the details of this energizing event.

At Pangaea Ventures, we invest in bold hard tech innovations reshaping the future of industry and solving our planet’s (and its people’s) most pressing challenges. Kanvas Biosciences is a quintessential example leveraging groundbreaking spatial biology technology and precision microbiome therapeutics to address untapped opportunities in medicine and beyond. Here’s why we’ve invested again.

Co-led by DCVC and Lions Capital with participation from the Gates Foundation, ATHOS, Germin8, Ki Tua Fund, Pangaea Ventures and others, the round will fund clinical trials for Kanvas’ lead drug candidates and more.

In Part 1 of the Agtech Reset series, we explored how a decade of misaligned capital and expectations left many ag and foodtech innovations stranded, even as fundamentals strengthened. In Part 2, we turn to the practical question: where, exactly, are the opportunities, and what does it mean to both fund and fix them.

The Agtech Reset Part 1 examines how agtech and foodtech went from hyper-growth to capital drought, why strong technologies were left stranded, and how compressing valuations plus persistent food-system pressures are creating a specialist investor opportunity.

With decades of experience scaling industrial businesses, Kravtsov will focus on expanding CarbonCure’s CO₂ utilization technology across more producers and regions.

The funding will accelerate commercialization and global deployment of pH7’s closed-loop platform, enabling economic recovery of critical minerals from low-grade ores, tailings, and complex feedstocks that were previously uneconomic to process.

Pangaea Ventures is excited to welcome Kandai Yamashita as our new investment lead in Tokyo, further strengthening Pangaea’s long-standing partnership model with corporate limited partners and Japan’s hard tech ecosystem.

Pangaea Venturesは、東京に於ける新たな投資担当として山下 寛大（Kandai Yamashita）を迎えることになりました。これにより、当社が長年培ってきたコーポレートLPとのパートナーシップモデルと日本のHard Tech Ecosystemとの繋がりをより一層強化していきます。

Aspect Biosystems has announced a $280M partnership with Government of Canada to accelerate development of its bioengineered cellular medicines for serious metabolic and endocrine diseases.

We’re often asked why our US office is in Phoenix. To us, the answer is clear. Arizona offers an unusually strong fit for hard tech: a rising startup hub, a deep pipeline of engineering and scientific talent, concentration in advanced manufacturing and semiconductors, and a supportive policy and business environment.

pH7 Technologies is expanding its Vancouver facility to boost North American recovery of critical platinum group metals from recycled materials, while cutting wastewater, energy use, and carbon footprint relative to conventional refining.

Kanvas Biosciences has received the green light to begin enrolling and treating patients in a Phase 1 clinical trial of KAN-004, a live biotherapeutic designed to treat immune checkpoint inhibitor–induced colitis